p95HER2 CAR-T / Vall d'Hebron Institute of Oncology, Hospital del Mar Medical Research Institute - LARVOL DELTA

An investigator-initiated first-in-human phase I study of autologous p95HER2.CAR-TECH2Me T cells in patients with HER2-positive advanced solid tumors: CATHERINE (ESMO 2026) - No abstract available

CAR T-Cell Therapy • Clinical • First-in-human • Metastases • New P1 trial • P1 data • Oncology • Solid Tumor • HER-2

First clinical evaluation of p95HER2.CAR-TECH2Me in HER2-positive solid tumors: CATHERINE phase I trial (ESGCT 2026) - No abstract available

CAR T-Cell Therapy • Clinical • P1 data • Oncology • Solid Tumor • HER-2

CATHERINE: A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. (clinicaltrials.gov) - P1 | N=15 | Recruiting | Sponsor: Vall d'Hebron Institute of Oncology | Not yet recruiting ➔ Recruiting

Enrollment open • Breast Cancer • Endometrial Cancer • Gastric Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2

CATHERINE: A Phase I Interventional Open-label, Non-randomized Dose-escalation Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Preliminary Anti-tumor Activity of Autologous p95HER2.CAR-TECH2Me T Cells in Patients With Selected Advanced Cancers. (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Vall d'Hebron Institute of Oncology

New P1 trial • Breast Cancer • Endometrial Cancer • Gastric Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • HER-2